Upgrade to SI Premium - Free Trial

Roche (RHHBY)

59.11 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Roche Q3 preview: UBS says 'FX impact turning to a tailwind' October 21, 2026 6:00 PM - StreetInsider Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 October 21, 2026 8:00 AM - BizWire RBC Capital on Roche Holding (ROG:SW) (RHHBY): 'Strong momentum into 3Q26 could make for a tricky set-up' October 19, 2026 9:31 AM - StreetInsider Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio October 19, 2026 1:01 AM - BizWire FDA approves Genentech's Enspryng for thyroid eye disease October 16, 2026 1:00 AM - StreetInsider FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) October 16, 2026 1:00 AM - BizWire Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss October 10, 2026 5:40 PM - BizWire FDA approves Genentech's Tecentriq for stage III colon cancer October 9, 2026 1:01 AM - StreetInsider FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer October 9, 2026 1:01 AM - BizWire Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC October 7, 2026 1:00 AM - PR NewsWire Flatiron Health's Breast Cancer Panoramic Dataset Surpasses One Million Patients, Enabling Real-World Research at Unprecedented Scale October 1, 2026 9:00 AM - BizWire Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends October 1, 2026 7:00 AM - BizWire Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions October 1, 2026 2:00 AM - BizWire Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine October 1, 2026 1:00 AM - BizWire Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis September 30, 2026 1:01 AM - BizWire Roche launches newborn screening test for three severe genetic conditions September 30, 2026 1:00 AM - PR NewsWire Flatiron Health Expands Global Panoramic Datasets With AI-Powered Breast Cancer and NSCLC Real-World Data for the UK, Germany, and Japan September 29, 2026 9:00 AM - BizWire Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon September 28, 2026 6:00 PM - BizWire Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN) September 23, 2026 1:00 AM - BizWire Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity September 22, 2026 1:05 AM - BizWire Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center September 17, 2026 2:30 PM - BizWire Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study September 17, 2026 1:00 AM - BizWire Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF380 at HSBC September 10, 2026 3:28 AM - StreetInsider FDA grants priority review to Genentech's Enspryng for rare disease MOGAD September 10, 2026 1:11 AM - StreetInsider U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments September 10, 2026 1:11 AM - BizWire RBC Capital Starts Roche Holding (ROG:SW) (RHHBY) at Outperform September 9, 2026 5:52 AM - StreetInsider Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF430 at Barclays September 8, 2026 5:39 AM - StreetInsider Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF415 at BofA Securities September 4, 2026 6:06 AM - StreetInsider Roche wins FDA nod for HER2 companion diagnostics in GEA August 26, 2026 2:52 PM - StreetInsider Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA August 26, 2026 2:52 PM - PR NewsWire Flatiron Health Expands NSCLC Panoramic Dataset With Comprehensive Biomarker Data Model, Enabling Precision Medicine Research at Unprecedented Scale August 25, 2026 9:00 AM - BizWire Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care August 24, 2026 7:00 AM - PR NewsWire Genentech Announces Manufacturing Expansion in Hillsboro, Oregon August 20, 2026 11:00 AM - BizWire Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility August 18, 2026 3:40 PM - BizWire Morgan Stanley Upgrades Roche (RHHBY) to Overweight August 7, 2026 2:52 AM - StreetInsider Morgan Stanley Upgrades Roche Holding (ROG:SW) (RHHBY) to Overweight August 7, 2026 2:52 AM - StreetInsider Roche expands cyclospora testing portfolio to support U.S. public health response August 6, 2026 8:30 AM - PR NewsWire Buy this biotech stock into Q2 earnings: Analyst August 1, 2026 4:00 AM - StreetInsider Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF434.50 at Bernstein SocGen Group July 27, 2026 9:30 AM - StreetInsider Roche wins FDA clearance for vaginitis PCR diagnostic test July 24, 2026 8:31 AM - StreetInsider Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis July 24, 2026 8:30 AM - PR NewsWire UBS Reiterates Buy Rating on Roche Holding (ROG:SW) (RHHBY) July 23, 2026 3:14 AM - StreetInsider Full Article List